$4.81
0.00% day before yesterday
Nasdaq, Dec 27, 10:04 pm CET
ISIN
US9216591084
Symbol
VNDA
Sector
Industry

Vanda Pharmaceuticals Inc. Stock price

$4.81
-0.38 7.32% 1M
-1.00 17.21% 6M
+0.59 13.98% YTD
+0.51 11.86% 1Y
-12.51 72.23% 3Y
-11.94 71.28% 5Y
-10.02 67.57% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.00 0.00%
ISIN
US9216591084
Symbol
VNDA
Sector
Industry

Key metrics

Market capitalization $280.46m
Enterprise Value $-87.86m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 4.83
EV/Sales (TTM) EV/Sales -0.46
P/S ratio (TTM) P/S ratio 1.47
P/B ratio (TTM) P/B ratio 0.52
Revenue growth (TTM) Revenue growth -9.91%
Revenue (TTM) Revenue $190.86m
EBIT (operating result TTM) EBIT $-37.48m
Free Cash Flow (TTM) Free Cash Flow $-18.20m
Cash position $376.26m
EPS (TTM) EPS $-0.28
P/E forward negative
P/S forward 1.41
EV/Sales forward negative
Short interest 8.25%
Show more

Is Vanda Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Vanda Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

Buy
67%
Hold
33%

Financial data from Vanda Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
191 191
10% 10%
100%
- Direct Costs 19 19
2% 2%
10%
172 172
11% 11%
90%
- Selling and Administrative Expenses 123 123
3% 3%
65%
- Research and Development Expense 79 79
11% 11%
41%
-30 -30
1,417% 1,417%
-16%
- Depreciation and Amortization 7.32 7.32
190% 190%
4%
EBIT (Operating Income) EBIT -37 -37
16,265% 16,265%
-20%
Net Profit -16 -16
239% 239%
-9%

In millions USD.

Don't miss a Thing! We will send you all news about Vanda Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vanda Pharmaceuticals Inc. Stock News

Positive
Seeking Alpha
8 days ago
Vanda Pharmaceuticals has returned to net-net status. Vanda has been building out their sales team to ramp up Fanapt and PONVORY distribution. I'm interested in buying the stock prior to FY 2024 results being announced in February.
Neutral
PRNewsWire
9 days ago
WASHINGTON , Dec. 20, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor for the treatment of polycythemia vera (PV), a form of a rare hematologic malignancy that is estimated to affect 1 in 2000 Ameri...
Neutral
Business Wire
12 days ago
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors' and officers' possible violations of state laws. If you own Vanda Pharmaceuticals stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with r...
More Vanda Pharmaceuticals Inc. News

Company Profile

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Head office United States
CEO Mihael Polymeropoulos
Employees 203
Founded 2002
Website www.vandapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today